SY vs SKIN

For growth investors, So-Young International Inc.

(SY) is the stronger pick with -2. 1% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). Analysts rate So-Young International Inc. (SY) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, So-Young International Inc.

(SY) delivered a total return of -64. 7%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: SY returned -82. 9% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Beauty Health Company (SKIN) is the lower-risk stock at 2.

00β versus So-Young International Inc. 's 2. 05β — meaning SY is approximately 3% more volatile than SKIN relative to the S&P 500. On balance sheet safety, So-Young International Inc. (SY) carries a lower debt/equity ratio of 12% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), So-Young International Inc.

(SY) is pulling ahead at -2. 1% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -28. 4% for So-Young International Inc.. Over a 3-year CAGR, SY leads at -4. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Beauty Health Company (SKIN) is the more profitable company, earning -3.

2% net margin versus -40. 2% for So-Young International Inc. — meaning it keeps -3. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SKIN leads at -6. 9% versus -42. 6% for SY. At the gross margin level — before operating expenses — SKIN leads at 65. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, SY (1.

6% yield) pays a dividend. SKIN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, So-Young International Inc.

(SY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (1. 6% yield). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SY: -82. 9%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SY (Healthcare) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

SY pays a dividend while SKIN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.